<DOC>
	<DOCNO>NCT00240643</DOCNO>
	<brief_summary>This study allow determination pharmacokinetic pharmacodynamics SB424323 relevant population . The data study use along data aid choosing appropriate dose later phase study .</brief_summary>
	<brief_title>Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke</brief_title>
	<detailed_description>A randomized , double blind , double dummy , parallel group , placebo control study evaluate pharmacodynamic pharmacokinetic response safety tolerability SB424323 ( 250 mg , 375 mg 500 mg ) administer twice daily 16 week , top aspirin ( 325 mg , qd ) men woman non valvular atrial fibrillation low intermediate risk stroke</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Patients non valvular atrial fibrillation follow : &lt; /= 60 year old heart disease . 60 year old heart disease risk factor . &gt; /=60 year old &lt; /=75 year old risk factor heart disease . Must able take aspirin . Previous heart attack stroke . History high blood pressure , diabetes prior blood clot . Liver kidney disease . Need antithrombotic antiplatelet drug . Need cardiovascular medicine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>non valvular atrial fibrillation</keyword>
	<keyword>stroke</keyword>
	<keyword>aspirin</keyword>
</DOC>